AU605669B2 - Therapeutic agents for the treatment of peptic ulcer disease - Google Patents

Therapeutic agents for the treatment of peptic ulcer disease Download PDF

Info

Publication number
AU605669B2
AU605669B2 AU28538/89A AU2853889A AU605669B2 AU 605669 B2 AU605669 B2 AU 605669B2 AU 28538/89 A AU28538/89 A AU 28538/89A AU 2853889 A AU2853889 A AU 2853889A AU 605669 B2 AU605669 B2 AU 605669B2
Authority
AU
Australia
Prior art keywords
compound
alkyl
dihydroxyhexyl
formula
denotes
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU28538/89A
Other languages
English (en)
Other versions
AU2853889A (en
Inventor
Harald Furrer
Ulrich Gebert
Masayoshi Goto
Masao Sakurai
Toshizo Tanaka
Erhard Wolf
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi Aventis KK
Original Assignee
Hoechst Japan Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoechst Japan Ltd filed Critical Hoechst Japan Ltd
Publication of AU2853889A publication Critical patent/AU2853889A/en
Application granted granted Critical
Publication of AU605669B2 publication Critical patent/AU605669B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)
AU28538/89A 1988-02-19 1989-01-17 Therapeutic agents for the treatment of peptic ulcer disease Ceased AU605669B2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP63-35484 1988-02-19
JP63035484A JP2661666B2 (ja) 1988-02-19 1988-02-19 抗消化性潰瘍剤

Publications (2)

Publication Number Publication Date
AU2853889A AU2853889A (en) 1989-08-24
AU605669B2 true AU605669B2 (en) 1991-01-17

Family

ID=12443024

Family Applications (1)

Application Number Title Priority Date Filing Date
AU28538/89A Ceased AU605669B2 (en) 1988-02-19 1989-01-17 Therapeutic agents for the treatment of peptic ulcer disease

Country Status (17)

Country Link
US (1) US5082845A (enExample)
EP (1) EP0330031B1 (enExample)
JP (1) JP2661666B2 (enExample)
KR (1) KR0133075B1 (enExample)
AT (1) ATE70182T1 (enExample)
AU (1) AU605669B2 (enExample)
DE (1) DE68900516D1 (enExample)
DK (1) DK74189A (enExample)
ES (1) ES2039719T3 (enExample)
GR (1) GR3003952T3 (enExample)
HU (1) HU204702B (enExample)
IE (1) IE61147B1 (enExample)
IL (1) IL89324A0 (enExample)
NZ (1) NZ228020A (enExample)
PH (1) PH27149A (enExample)
PT (1) PT89757B (enExample)
ZA (1) ZA891241B (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2661666B2 (ja) * 1988-02-19 1997-10-08 ヘキスト薬品工業株式会社 抗消化性潰瘍剤
DD298051A5 (de) * 1989-08-16 1992-02-06 ��@���������@�������k�� Verfahren zur herstellung eines therapeutischen agens zur behandlung von verdauungskrankheiten
IT1240843B (it) * 1990-05-24 1993-12-17 Malesci Istituto Farmacobiologico Derivati xantinici 1-7 sostituiti ad attivita' antiasmatica, loro sali fisiologicamente accettabili, loro composizioni farmaceutiche e procedimento per la loro preparazione.
JP2549480B2 (ja) * 1991-12-10 1996-10-30 ヘキストジャパン株式会社 排尿障害改善剤
EP0570831A2 (de) * 1992-05-20 1993-11-24 Hoechst Aktiengesellschaft Verwendung von Xanthinderivaten zur Behandlung von Nervenschädigungen nach Unterbrechung der Blutzirkulation
US5354756A (en) * 1993-01-12 1994-10-11 Cell Therapeutics, Inc. Olefin-substituted long chain xanthine compounds
US5620676A (en) * 1994-03-08 1997-04-15 The United States Of America As Represented By The Department Of Health And Human Services Biologically active ATP analogs
BRPI0908107A2 (pt) 2008-02-29 2019-09-24 Concert Pharmaceuticals Inc composto derivado de xantina substituída, composição farmacêutica que compreende esse composto, métodos de tratamento de uma enfermidade ou condição em um paciente com necessidade do mesmo, método de tratamento de enfermidade crônica dos rins, do fígado, relacionada com diabetes e de claudicação intermitente
US20110053961A1 (en) 2009-02-27 2011-03-03 Concert Pharmaceuticals, Inc. Substituted xanthine derivatives

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH608236A5 (enExample) * 1974-01-22 1978-12-29 Wuelfing J A Fa
DE2432702C2 (de) * 1974-07-08 1983-01-20 Hoechst Ag, 6000 Frankfurt Verfahren zur Herstellung von Hydroxyalkylxanthinen
US4207321A (en) * 1977-04-02 1980-06-10 Hoechst Aktiengesellschaft Pharmaceutical compositions containing xanthines
EP0157098A1 (en) * 1980-06-21 1985-10-09 Beecham Wuelfing GmbH & Co KG Xanthine derivatives, pharmaceuticals compositions containing them and a process for their preparation
DE3138397A1 (de) * 1981-09-26 1983-04-07 Hoechst Ag, 6230 Frankfurt "arzneimittel, darin enthaltene vicinale dihydroxyalkylxanthine und herstellungsverfahren fuer diese xanthinverbindungen"
US4636507A (en) * 1984-04-30 1987-01-13 Hoechst-Roussel Pharmaceuticals Inc. Host defense mechanism enhancement
GB8418430D0 (en) * 1984-07-19 1984-08-22 Beecham Wuelfing Gmbh & Co Kg Treatment
DE3508097A1 (de) * 1984-07-21 1986-02-06 Hoechst Ag, 6230 Frankfurt Kombinationspraeparat aus xanthinderivaten und o-acetylsalicylsaeure bzw. deren pharmakologisch vertraeglichen salzen und dessen verwendung
DE3525801A1 (de) * 1985-07-19 1987-01-22 Hoechst Ag Tertiaere hydroxyalkylxanthine, verfahren zu ihrer herstellung, die sie enthaltenden arzneimittel und ihre verwendung
US4772607A (en) * 1986-05-20 1988-09-20 Warner-Lambert Company Dialkenyl derivatives of xanthine, pharmaceutical compositions and methods of use therefor
JPS63225317A (ja) * 1986-10-06 1988-09-20 Hoechst Japan Kk 抗消化性潰瘍剤
JP2661666B2 (ja) * 1988-02-19 1997-10-08 ヘキスト薬品工業株式会社 抗消化性潰瘍剤

Also Published As

Publication number Publication date
EP0330031B1 (en) 1991-12-11
JPH01211524A (ja) 1989-08-24
HU204702B (en) 1992-02-28
PT89757A (pt) 1989-10-04
EP0330031A1 (en) 1989-08-30
KR890012652A (ko) 1989-09-18
ES2039719T3 (es) 1993-10-01
DE68900516D1 (de) 1992-01-23
IE61147B1 (en) 1994-10-05
IE890514L (en) 1989-08-19
JP2661666B2 (ja) 1997-10-08
ATE70182T1 (de) 1991-12-15
IL89324A0 (en) 1989-09-10
NZ228020A (en) 1991-07-26
US5082845A (en) 1992-01-21
KR0133075B1 (ko) 1998-04-17
PT89757B (pt) 1994-03-31
AU2853889A (en) 1989-08-24
DK74189D0 (da) 1989-02-17
PH27149A (en) 1993-04-02
HUT49283A (en) 1989-09-28
DK74189A (da) 1989-08-20
GR3003952T3 (enExample) 1993-03-16
ZA891241B (en) 1989-10-25

Similar Documents

Publication Publication Date Title
CA2045478C (en) Xanthine compounds
EP1319003B1 (en) Xanthine phosphodiesterase v inhibitors
CA1198436A (en) 2-phenoxyalkyl-1,2,4-triazol-3-one antidepressants
AU2001291022A1 (en) Xanthine phosphodiesterase v inhibitors
AU605669B2 (en) Therapeutic agents for the treatment of peptic ulcer disease
JP2002533395A (ja) 痛みを処置するための（２−イミダゾリン−２−イルアミノ）キノキサリン誘導体
PL161362B1 (pl) Sposób wytwarzania nowych 1-/1H-imidazolilo-4/alkilobenzamidów PL PL PL PL PL PL PL PL PL
US4314943A (en) Heterocyclic substituted aryloxy 3-indolyl-tertiary butylaminopropanols
AU624987B2 (en) Therapeutic agents for the treatment of peptic ulcer disease
JP2726999B2 (ja) イミダゾ［２，１−ｂ］ベンゾチアゾール誘導体及び該化合物を有効成分とする抗潰瘍剤
AU640831B2 (en) Process for preparing benzo(c)phenanthridinium derivatives, and novel compounds prepared by said process
WO1982001874A1 (en) 2-(1,4-benzodoioxan-2-ylalkyl)imidazoles useful as antidepressants
JPH07165754A (ja) ヘテロアリールピペリジン、その製造方法およびそれを含有する医薬組成物
AU597233B2 (en) Bicyclic lactams, processes for their preparation and their use and formulations containing these compounds
EP0102580B1 (en) Substituted 1,3,4-benzotriazepines, a method of preparing the same and theire use as medicaments
DK160303B (da) Analogifremgangsmaade til fremstilling af 5'-(2-amino-4-pyridyl)-1',2',4'-triazol-forbindelser eller farmaceutisk acceptable syreadditionssalte deraf samt 5'-(2-halogen-4-pyridyl)-1',2',4',-triazol-forbindelser til anvendelse ved fremgangsmaaden
KR960008246B1 (ko) 우레아 유도체
EP0463212A1 (en) Imidazo[2,1-b]thiazole compound anti-ulcer agent containing the same
JPH04279586A (ja) キサンチン誘導体
JPS62246560A (ja) 新規なビペラジン誘導体および該化合物を有効成分とする抗潰瘍薬
JPH03218378A (ja) キサンチン誘導体